LCTX

0.77195.87%
IC

Ioana C. Hone

VP of Corporate Communications & Director of Investor Relations

Ms. Ioana C. Hone served as Director of Investor Relations at Lineage Cell Therapeutics, Inc. (formerly known as BioTime, Inc.) until March 2019 and serves as its Director of Investor Relations and also serves as its Vice President of Corporate Communications from November 2026. Ms. Hone serves as Head of Investor Relations at Savara Inc. Ioana C. Hone served as Director of Investor Relations at Mast Therapeutics, Inc. since June 2010. she Ioana brings years of investor relations and corporate communications experience across the biotechnology and life sciences industries. She specializes in translating complex science and clinical development into clear, compelling narratives and building integrated communications strategies that support companies through periods of growth, capital formation, clinical advancement and corporate transformation. Throughout her career, she has served as a strategic advisor to executive leadership teams and boards of directors, helping shape corporate positioning, messaging and stakeholder engagement strategies designed to strengthen credibility, expand visibility and support long-term value creation. Her experience includes roles with public biotechnology and wellness companies including Savara, Inc., Global Blood Therapeutics, Inc., Mast Therapeutics, Inc. and LifeVantage Corporation, among others. In 2012, she co-founded the Annual Sickle Cell Disease Therapeutics Conference, a forum dedicated to advancing discussion around emerging science, therapeutic development and the treatment of people living with sickle cell disease. She helped organize the 2014 Patient-Focused Drug Development forum, The Voice of the Patient in Sickle Cell Disease, with the FDA, which contributed to the subsequent publication of The Voice of the Patient: Sickle Cell Disease report. These efforts helped broaden awareness of sickle cell disease, strengthen engagement between the patient community and drug developers and elevate the disease within the broader biotechnology and investment communities. More recently, she co-founded the Spinal Cord Injury (SCI) Investor Symposium, an initiative designed to bring together the SCI community, advocates, researchers, biotechnology companies and investors. The symposium emphasizes partnership with individuals affected by spinal cord injury and community organizations to ensure their perspectives help inform the development of potential new therapies. she is passionate about advancing innovative treatments for serious and underserved medical conditions and believes that effective communication can serve as a bridge between scientific innovation, investment and the individuals that those innovations are ultimately intended to serve. She earned a B.A. in International Studies, with a minor in Political Science, from the University of California, Irvine.

Positions